News | June 23, 2022
Alembic Pharmaceuticals shows growth in May 2022
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US $ 102 million for twelve months ending December 2021 according to IQVIA
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
The tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency
Subscribe To Our Newsletter & Stay Updated
